Cabometyx 20 mg, 40 mg, 60 mg Film-coated tablets
PDF Leaflet Revision Date: 12 December 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of advanced renal cell carcinoma and hepatocellular carcinoma.
Dosage (summary)
60 mg once daily; reduce to 40 mg or 20 mg if needed.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Avoid during pregnancy; discontinue breastfeeding during treatment and for 4 months after.
Key Drug Interactions
- CYP3A4 inhibitors
- CYP3A4 inducers
- P-glycoprotein substrates
Contraindications
- Hypersensitivity to cabozantinib
Common side effects
- Diarrhoea
- Fatigue
- Nausea
- Hypertension
- Palmar-plantar erythrodysaesthesia syndrome
Counselling Points
- Take on an empty stomach
- Monitor for signs of liver dysfunction
- Report severe side effects immediately
Serious warnings
- Severe haemorrhage
- GI perforations
- Hepatic encephalopathy
- Thromboembolic events
Important Disclaimer
The Cabometyx 20 mg, 40 mg, 60 mg Film-coated tablets professional information leaflet below is the property of Acino Pharma and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
